Physician profile
Van T Le
NPI 1811336761
$988.91
in general payments reported to CMS, 2019-2025
23 companies · $229 in 2025
The $229 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.04 · 2020: $40.00 · 2021: $13.84 · 2022: $199 · 2023: $209 · 2024: $236 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $595 · Education: $79.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $594.59 |
| Education | $79.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $149.89 | 2022-2024 | Dupixent |
| Genzyme Corporation | $128.77 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $100.52 | 2019-2024 | Fasenra, Tezspire |
| Mylan Specialty L.P. | $100.30 | 2019-2023 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.50 | 2019-2025 | Ofev, Jascayd |
| Grifols USA, LLC | $50.69 | 2021-2024 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $48.29 | 2024-2025 | |
| Glaxosmithkline, LLC. | $43.27 | 2019-2025 | Nucala |
| Inspire Medical Systems, INC. | $41.68 | 2023-2025 | Inspire |
| Amgen INC. | $31.34 | 2022 | |
| Inogen, INC. | $24.85 | 2025 | |
| Philips North America LLC | $23.82 | 2024 | (Ak6) Vest Therapy |
| Pfizer INC. | $22.02 | 2025 | |
| Baxter Healthcare | $20.98 | 2023 | Hillrom - Life 2000 Ventilation System |
| Verona Pharma, INC. | $18.89 | 2025 | Ohtuvayre |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covis Pharma Gmbh | $18.73 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.00 | 2025 | Glassia |
| Gilead Sciences, INC. | $17.43 | 2023 | |
| United Therapeutics Corporation | $15.86 | 2024 | |
| Merck Sharp & Dohme LLC | $13.97 | 2023 | |
| Boston Scientific Corporation | $13.66 | 2022 | |
| Advanced Respiratory, INC | $13.40 | 2020 | |
| Nabriva Therapeutics, Plc | $12.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Van Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.